drugset / Trial / NCT02886793

Cell Proliferation in Pulmonary Hypertension. FDG-PET Comparison Between Patients and Healthy Subjects

NCT02886793

Phase 1/2 Completed 65 enrolled Joan Albert Barbera Mir
NaSingle-groupOpen-labelDiagnostic

Summary

Pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) are serious diseases with poor prognosis despite recent advances. Currently, pulmonary hypertension (PH) is considered a cell proliferative disorder, which has not been adequately characterized due to the lack of markers. A better understanding of the mechanisms that regulate this proliferative disorder will allow the identification of new therapeutic targets for HP. The objective of the project is to identify cell proliferative processes in severe forms of PH. Patients with PAH (n=20), CTEPH (n=20) and healthy controls (n=20) will undergo characterization of microRNAs (miRNAs) contained within circulating microparticles (MPs) analysis and mitochondrial functionality and FDG-PET to compare cell metabolism in the lungs and the right ventricle between patients and controls.

Timeline

Start
2016-06
Primary completion
2018-07
Completion
2018-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fludeoxyglucose Diagnostic / imaging agent